Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Esophageal cancer is a common malignant tumor in china, occupies the second place of
malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University